LOS ANGELES--(BUSINESS WIRE)--Response Genetics, Inc. (NASDAQ: RGDX) announced today that its ResponseDX: Lung™ and ResponseDX: Colon™ tests are now available to select medical institutions and practice groups through its CLIA-registered laboratory. ResponseDX: Lung™ and ResponseDX: Colon™ are PCR-based tests that help guide therapeutic treatment decisions in patients with non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The tests are in their initial launch phase and are available only to pre-qualified institutions at this time.
